AE Monitoring and Management With Targeted Therapies in NSCLC
Panelists discuss how ongoing trials may reshape the treatment landscape for HER2-altered NSCLC, particularly regarding the roles of ADCs and TKIs in managing both HER2-mutated and HER2-overexpressing NSCLC.
EP: 1.An Overview of HER2 Alterations in NSCLC and Implications for Treatment
EP: 2.Biomarker Testing in NSCLC: Best Practices for Personalized Medicine
EP: 3.T-DXd in HER2-Overexpressing and HER2-Mutated NSCLC: Clinical Trial Data and Insights
EP: 4.ADCs, TKIs, and the Evolving Treatment Landscape in HER2-Altered NSCLC
EP: 5.AE Monitoring and Management With Targeted Therapies in NSCLC
EP: 6.Thoracic Oncologist Perspectives on a Rapidly Evolving Treatment Landscape
EP: 7.Identifying HER2 Mutations for T-DXd Use in NSCLC
- (Rohit asks Levy) Please briefly highlight other trials of note and how the treatment landscape in HER2-altered NSCLC may evolve over time. What might be the positioning of ADCs, TKIs, and other treatment modalities in the treatment landscapes for HER2-mutated and HER2-overexpressing NSCLC?
NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy
August 17th 2021This article reviews NCCN Guideline updates regarding the use of genomic assays in predicting the benefit of extended adjuvant endocrine therapy in patients with HR+ breast cancer and includes insights from Lee S. Schwartzberg, MD, of West Cancer Center at the University of Tennessee Health Science Center in Memphis, TN.
Individualizing Extended Adjuvant Therapy in HR+ Breast Cancer
June 15th 2021This article reviews individualizing extended adjuvant therapy for patients with HR+ breast cancer and includes insights from Vijayakrishna (V. K.) Gadi, MD, PhD, of the University of Illinois in Chicago, and Reshma L. Mahtani, DO, of the University of Miami Health System in Deerfield Beach, FL.
Advances in Later-Line Management of Relapsed/Refractory Follicular Lymphoma
May 27th 2021This article reviews advances in later-line management of relapsed/refractory follicular lymphoma. This article also features insights from oncology expert Sameh Gaballa, MD, of Moffitt Cancer Center in Tampa, Florida.
